A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project

Academic Article

Abstract

  • In an ongoing prospective randomized study, 113 evaluable patients have received either a three‐drug combination that included cyclophosphamide, Adriamycin and 5‐fluorouracil (CAF) or a five‐drug combination including cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features. Cancer 40:625–632, 1977. Copyright © 1977 American Cancer Society
  • Published In

  • Cancer  Journal
  • Author List

  • Smalley RV; Carpenter J; Bartolucci A; Vogel C; Krauss S
  • Start Page

  • 625
  • End Page

  • 632
  • Volume

  • 40
  • Issue

  • 2